This is an old revision of this page, as edited by Beetstra (talk | contribs) at 14:11, 7 August 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEBI').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:11, 7 August 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEBI').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.238.211  |
| Chemical and physical data | |
| Formula | C15H14N4O6S2 |
| Molar mass | 410.427 g.mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent, with 2 dosage forms, capsule or oral suspension. It is marketed by Shionogi USA under the trade name Cedax.
It is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli (K. pneumoniae, K. oxytoca), Proteus vulgaris, P. mirabils, P. providence, Salmonella sp., Shigella sp., Enterobacter sp. and Streptococcus sp.
Clinical use
Main article: CephalosporinIndications
Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. It is also indicated for pneumonia, infections of the urinary tract, enteritis and gastroenteritis.
Adverse reactions
In studies made in 3,000 patients ceftibuten was well tolerated. Most frequent reactions were gastrointestinal and nauseas.
Formulations
Ceftibuten is available as capsules containing 400 mg, and a powder for oral suspension containing 90 mg per 5 ml.